

had an interrupted repeated myoclonus, each last for few seconds. This cluster of seizures spontaneously stopped and did not recur. She never had lost her consciousness. Clinical examination did not show any neurological abnormality. Since admission till the onset of the convulsions she had normal temperature, O_2 saturation, serum electrolytes and serum glucose. As planned she received peripheral blood stem cells transplantation on twelfth and thirteenth February 2005, and she was successfully engrafted on 1st March 2005.

Phenytoin is a widely used prophylaxis to prevent BU induced seizures. The researches in this field virtually studied the conventional daily 4 doses of oral BU, while in this study we used the single daily dose of iv BU regimen.³ Our patient had seizures in spite of a prior regimen pharmacokinetic study, monitoring of serum BU level and achieving a therapeutic serum phenytoin level. More research is expected to study this single daily dose iv BU regimen and there may be a need to investigate for other(s) effective and safe alternative seizures prophylaxis.⁵

Received 16th May 2005. Accepted for publication in final form 19th December 2005.

From the Department of Hematology, Sultan Qaboos University Hospital, Alkhod, Muscat, Sultanate of Oman. Address correspondence and reprint requests to: Dr. David Denison, Consultant Hematologist and Director of BMT, Sultan Qaboos University Hospital, Alkhod, Muscat, Sultanate of Oman. Tel. +968 99339708/ +968 24413462. Fax. +968 24413419. E-mail: aymanusam@hotmail.com

References

1. La Morgia, Mondini S, Guarino M, Bnifazi F, Cirignotta F. Busulfan neurotoxicity and EEG abnormalities: a case report. *Neurol Sci* 2004; 25: 95-97.
2. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan level on the outcome of transplantation. *Blood* 1997; 89: 3055-3060.
3. Jenke A, Freiberg-Richter J, Jone C, Knoth H, Schleyer E, Bornhauser M. Targeting Once-daily iv BU in combination with fludarabine before allogenic hematopoietic transplantation. *Bone Marrow Transplant* 2005; 35: 627-628.
4. Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, Galambrun C, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. *Bone Marrow Transplant* 2001; 28:743-751.
5. Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H. Lorazepam for seizure prophylaxis during high dose busulfan administration: Clinical Trial. *Bone Marrow Transplant* 2002; 29: 963-965.

Chlorambucil therapy in children with steroid-resistant nephrotic syndrome

Jameela A. Kari, FRCPC, FRCP (UK),
Abdulmohsen Alkushi, MSc, FRCPC,
Hammad O. Alshaya, FRCPC, FRCP(UK).

Chlorambucil (CHL) had been used as treatment for childhood nephrotic syndrome (NS) for more than half a century.¹ It was used mainly in children with steroid sensitive nephrotic syndrome (SSNS) as steroid sparing agent in those with frequent relapsing or steroid dependent course.² However, it was observed to result in higher rates of severe side effects and recommended as a second line drug after cyclophosphamide (CYC), which is considered as safer alkylating agent.² The alkylating agents have been used for treating steroid resistant nephrotic syndrome (SRNS).² However, CYC was used in most of the studies,³ while CHL was used only rarely.^{4,5} Elzouki et al showed in a small study that CHL induced complete or partial remission in patients with SRNS caused by either focal segmental glomerulosclerosis (FSGS) or mesangial proliferative glomerulonephritis (MPGN).⁴

In this retrospective study, we report our results of using CHL in children with SRNS secondary to IgM nephropathy, FSGS or diffuse mesangial hypercellularity (DMH). All patients presented to our unit over 20 months period (from February 2002 until June 2004) and were diagnosed as SRNS were recruited. Steroid resistant nephrotic syndrome was defined as a failure to go into remission after 4 weeks of prednisolone therapy at a dose of 60 mg/m²/day, plus 3 intravenous doses of methylprednisolone (600 mg/m²/day or 30 mg/kg/day) on alternate days. We had 7 patients with SRNS. All patients were females. The median (range) age at presentation was 4 (2-9) years. All except 2 were Arab in origin. All studied children were primary non-responders to prednisolone and 2 were also resistant to intravenous cyclophosphamide course. All the 7 children were treated with CHL (0.1-0.2 mg/kg/day) for 8-12 weeks. The mean \pm SD accumulative dose was 10.1 \pm 3.3 (7.0-15.2) mg/kg. All patients were continued on oral prednisolone 40mg/m² on alternate days and received enalapril (0.5-1 mg/kg) throughout the CHL therapy. Two patients achieved complete remission after 12 weeks of CHL therapy. One patient remained in remission for 2 years following CHL therapy and one patient had a relapse once after 1.5 years of follow up, which responded to prednisolone promptly. She had been on

Table 1 - Laboratory data before and after chlorambucil therapy in individual patients.

Patient's no.	Age at onset (years)	Sex	Histo-pathology	Pre-therapy			Duration of therapy (weeks)	Accumulative dose (mg/kg)	Post-therapy		
				S. alb (g/l)	S.cr (umol/l)	Urine protein			S. alb (g/l)	S.cr (umol/l)	Urine protein
1	4	F	IgM nephropathy	19	21	3+	12	14	37	22	-ve
2	2.5	F	IgM nephropathy	6	20	3+	12	15.2	38	24	-ve
3	2	F	DMH	4	19	3+	8	10.3	6	10	3+
4	5	F	IgM nephropathy	23	13	3+	8	8.6	24	11	2+
5	3.5	F	IgM nephropathy	15	31	3+	8	7.3	19	35	3+
6	7.5	F	IgM nephropathy	10	41	3+	8	8.5	10	68	3+
7	9	F	FSGS	21	85	3+	8	7	29	55	2+

F - female, IgM - immunoglobulin M, DMH - diffuse mesangial hypercellularity, FSGS - focal segmental glomerulosclerosis, S.alb - serum albumin, S.cr - serum creatinine, -ve = negative

one year remission. Two patients received CYC of 500 mg/m² per month for 6 doses before CHL therapy. The rest of the patients did not respond after 8 weeks of CHL therapy (Table 1). All of them except one were treated subsequently with Cy A. Two patients achieved complete remissions on Cy A while one patient achieved partial remission only. One patient was treated with CyA initially as the histopathology showed FSGS. However, she was treated with CHL when she showed sign of CyA toxicity and achieved partial remission after 8 weeks. No side effect was observed in any of the patients. None of the patients had leucopenia, hemorrhagic cystitis, infection, vomiting or alopecia. Our finding suggests that CHL is of therapeutic value in inducing remissions in children with SRNS secondary to IgM nephropathy. This agrees with previous reports of using it in SRNS caused by other histopathological forms.^{4,5} Pascual et al reported that CHL is effective in SRNS caused by MCD5 and Elzouki et al reported that CHL induced complete remission in 3 out of 4 patients with FSGS.⁴ One patient in this study experienced partial remission and one patient with SRNS caused by MPGN achieved complete remission. The 2 children who achieved complete remission in our study received 12 weeks course of CHL and higher accumulative dose (15.2 and 14mg/kg) than the non-responders who received 8 weeks course with a lower accumulative dose. We did not observe any side effects in our patient. However, CHL is known to cause many side effects.² Leucopenia occurs in approximately one of 3 patients receiving CHL and infection in 6.3%.² Children who received CHL are also at increased risk of developing malignancies (approximately 0.6%). However, the reported cases received longer duration and higher total accumulative total dose.^{2,4} The Gonadal toxicity is also a risk with CHL therapy particularly in males.²

It was estimated that CHL at a dose of 17 mg/kg with concomitant steroid may be safe.² However, the risk is minimized with a total dose of 7-10 mg kg. Seizures were also reported in 3.4-8% of children treated with CHL.²

We conclude that CHL therapy in a total accumulative dose of 15 mg/kg and 12 weeks duration could achieve complete remission in children with SRNS secondary to IgM nephropathy. Further randomized controlled studies are required.

Received 25th September 2005. Accepted for publication in final form 3rd January 2006.

From the Departments of Pediatrics (Kari, Alshaya) and Pathology (Alkushi), King Abdul-Aziz University Hospital, Jeddah, Kingdom of Saudi Arabia. Address correspondence and reprint requests to: Dr. Jameela Kari, Department of Pediatrics, King Abdul-Aziz University Hospital, PO Box 80215, Jeddah 21589, Kingdom of Saudi Arabia. Tel. +966 55677904. Fax. +966 (2) 6732410. E-mail: jkari@doctors.org.uk

References

1. Leveque B, Debauchez C, Deflandre L, Marie J. [Chlorambucil in the treatment of idiopathic nephrotic syndrome without glomerular lesions in childhood. Apropos of 30 cases] Le chlorambucil dans le traitement du syndrome nephrotique idiopathique sans lesion glomerulaire, chez l'enfant. A propos de 30 observations. *Ann Pediatr (Paris)* 1969; 16: 13-23.
2. Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. *Pediatr Nephrol* 2001; 16: 271-282.
3. Alshaya HO, Al-Maghrabi JA, Kari JA. Intravenous pulse cyclophosphamide-is it effective in children with steroid-resistant nephrotic syndrome? *Pediatr Nephrol* 2003; 18: 1143-1146.
4. Elzouki AY, Jaiswal OP. Evaluation of chlorambucil therapy in steroid-dependent and cyclophosphamide-resistant children with nephrosis. *Pediatr Nephrol* 1990; 4: 459-462.
5. Pascual JF, Molina M, Lopez J. Long-term assessment of chlorambucil in children with nephrotic syndrome who fail to respond adequately to corticosteroids. *Contrib Nephrol* 1981; 27: 65-74.